A new study offers insights into the relative efficacy of various treatments for alopecia areata (AA), suggesting that ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Regeneron Pharmaceuticals has recently launched a Phase 2 trial, testing the waters with a potential breakthrough in melanoma ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

In 2022, over 1 billion people were affected by obesity, driving innovation in therapeutic advancements. Emerging treatments focus on appetite contro ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Stocks are trading near record highs, and Wall Street expects them to continue their march higher over the next year.Analysts expect the S&P 500 to rise 7.5% to nearly 6,700 over the next 12 months, ...